Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy

NCT03468335 is registered in ClinicalTrials.gov with AIO-Studien-gGmbH as lead sponsor.

NCT NCT03468335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03468335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
Lead sponsor
AIO-Studien-gGmbH
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2018
Completion date
May 31, 2022
Enrollment
151 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic cancer, metastatic pancreatic cancer